The short version of LC-MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-23. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
The first mountain-building tectonic plate collision that initiated the construction of what are today the Appalachians occurred at least a billion years ago when the pre-North American craton called Laurentia collided with at least one other craton — Amazonia. All the other cratons of the earth also collided at about this time to form the supercontinent Rodinia and were surrounded by one single ocean. (It is possible that the cratons of Kalahari, and Rio Plato, were also part of that early collision since they were present as Rodinia broke up). Mountain-building referred to as the Grenville Orogeny occurred along the boundaries of the cratons. The present Appalachian Mountains have at least two areas which are made from rock formations that were formed during this orogeny - the Blue Ridge Mountains and the Adirondacks.
It is commonly believed that during the Middle Ages, pepper was often used to conceal the taste of partially rotten meat. No evidence supports this claim, and historians view it as highly unlikely; in the Middle Ages, pepper was a luxury item, affordable only to the wealthy, who certainly had unspoiled meat available, as well. In addition, people of the time certainly knew that eating spoiled food would make them sick. Similarly, the belief that pepper was widely used as a preservative is questionable; it is true that piperine, the compound that gives pepper its spiciness, has some antimicrobial properties, but at the concentrations present when pepper is used as a spice, the effect is small. Salt is a much more effective preservative, and salt-cured meats were common fare, especially in winter. However, pepper and other spices played a role in improving the taste of long-preserved meats. Archaeological evidence of pepper consumption in late medieval Northern Europe comes from excavations on the Danish-Norwegian flagship, Gribshunden, which sank in the summer of 1495. In 2021, archaeologists recovered more than 2,000 peppercorns from the wreck, along with a variety of other spices and exotic foodstuffs including clove, ginger, saffron, and almond. The ship was carrying King Hans to a political summit at the time of its loss. The spices were likely intended for feasts at the summit, which would have included the Danish, Norwegian, and Swedish Councils of State.
== Expert reviews of the evidence == Letby has maintained that she is innocent of the offences for which she was convicted. Following the trials, a number of medical, statistical and other scientific experts have criticised the prosecution's evidence. The defence have been criticised for failing to call any of their own expert witnesses at trial. In 2025, a panel of experts convened by neonatologist Shoo Lee, provided with the infants' records and other trial evidence by Letby's legal representatives, published an assessment of the cases which presented alternative explanations for all of the deaths and collapses. The infants' families and the prosecution's lead expert witness have disputed these findings. The Court of Appeal has previously rejected challenges to the safety of the convictions.
=== Side effects === The most common side effects during treatment with vasopressin are dizziness, angina, chest pain, abdominal cramps, heartburn, nausea, vomiting, trembling, fever, water intoxication, pounding sensation in the head, diarrhoea, sweating, paleness, and flatulence. The most severe adverse reactions are myocardial infarction and hypersensitivity.
Sources: en.wikipedia.org
== Function == cADPR is a cellular messenger for calcium signaling. It stimulates calcium-induced calcium release at lower cytosolic concentrations of Ca2+. The primary target of cADPR is the endoplasmic reticulum Ca2+ uptake mechanism. cADPR mobilizes Ca2+ from the endoplasmic reticulum by activation of ryanodine receptors, a critical step in muscle contraction. cADPR also acts as an agonist for the TRPM2 channel, but less potently than ADPR. cADPR and ADPR act synergistically, with both molecules enhancing the action of the other molecule in activating the TRPM2 channel. Potentiation of Ca2+ release by cADPR is mediated by increased accumulation of Ca2+ in the sarcoplasmic reticulum.
=== Competing narratives === In the years immediately following the revolution, narratives applied both by Romanians and the international audience competed for an interpretation of the events of 1989. Within Romania, myths interpreting it as "false" or "stolen" by the FSN correlated to one's level of disagreement with the political organization, while those painting the events as a pure, "spontaneous revolution" largely aligned with support for the FSN. In addition, the FSN itself attempted to construct its own narrative of the revolution, with its leaders placed abruptly at the center by popular will. This interpretation was largely challenged by FSN opponents.
Chipotle Mexican Grill, Inc. ( chih-POAT-lay), also known simply as Chipotle, is an American multinational chain of fast casual restaurants specializing in bowls, tacos, and Mission burritos made to order in front of the customer. As of December 2025, Chipotle has 4,000 locations. Its name derives from chipotle, the Nahuatl name (from chilpoctli) for a smoked and dried jalapeño chili pepper. Chipotle was one of the first chains of fast casual restaurants. It was founded by Steve Ells on July 13, 1993. Ells was the founder, chairman, and CEO of Chipotle. He was inspired to open the restaurant after visiting taquerias and burrito shops in San Francisco's Mission District while working as a chef. Ells wanted to show customers that fresh ingredients could be used to quickly serve food. Chipotle had 16 restaurants (all in Colorado) when McDonald's became a major investor in 1998. By the time McDonald's fully divested itself from Chipotle in 2006, the chain had grown to over 500 locations. With more than 2,000 locations, Chipotle had a net income of US$475.6 million and a staff of more than 45,000 employees in 2015. By 2025, Chipotle had restaurants in 48 states and the District of Columbia but not in the states of Alaska or Hawaii nor in the American overseas territories of Puerto Rico, the Virgin Islands, American Samoa, or Guam.
A benefit of this pathogen-induced model is that it shows Alzheimer's-like symptoms, while also exhibiting Aβ pathology. This is present in both familial and sporadic AD, making it a more inclusive model. Additionally, the level of Aβ can be controlled, making it an ideal candidate for AD investigation. However, damage to the brain tissue during ICV injection must be minimized to prevent neuronal injury. This requires a highly trained individual or surgeon.
Anabolic-androgenic steroids (AAS) were first isolated, identified and synthesized in the 1930s, and are now used therapeutically in medicine to induce bone growth, stimulate appetite, induce male puberty, and treat chronic wasting conditions, such as cancer and AIDS. Anabolic steroids also increase muscle mass and physical strength, and are therefore used in sports and bodybuilding to enhance strength or physique. Known side effects include harmful changes in cholesterol levels (increased low-density lipoprotein and decreased high-density lipoprotein), acne, high blood pressure, and liver damage. Some of these effects can be mitigated by taking supplemental drugs. AAS use in American sports began in October 1954 when John Ziegler, a doctor who treated American athletes, went to Vienna with the American weightlifting team. There he met a Russian physician who, over "a few drinks", repeatedly asked "What are you giving your boys?" When Ziegler returned the question, the Russian said that his own athletes were being given testosterone. Returning to America, Ziegler tried low doses of testosterone on himself, on the American trainer Bob Hoffman and on two lifters, Jim Park and Yaz Kuzahara. All gained more weight and strength than any training programme would produce but there were side-effects. Ziegler sought a drug without after-effects and hit upon the anabolic steroid methandrostenolone, first made in the US in 1958 by Ciba and marketed as Dianabol (colloquially known as "d-bol").
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.